20
Aug

German drug developer MorphoSys is pairing up with Emergent BioSolutions to get its hands on an early-stage prostate cancer treatment, signing a deal worth up to $183 million for a promising antibody.

…read more

Source: MorphoSys bets on Emergent BioSolutions’ cancer contender in $183M deal

    

0 No comments